Samuel Kintz Sells 12,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $21.66, for a total transaction of $259,920.00. Following the completion of the transaction, the chief executive officer now directly owns 1,075,525 shares in the company, valued at approximately $23,295,871.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Samuel Kintz also recently made the following trade(s):

• On Tuesday, May 28th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $23.18, for a total transaction of $278,160.00.
• On Thursday, April 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.89, for a total transaction of $202,680.00.
• On Thursday, April 11th, Samuel Kintz sold 47,709 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.04, for a total transaction of $1,194,633.36.

Enliven Therapeutics Stock Down 0.3 %

Shares of ELVN stock opened at $23.37 on Friday. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -12.11 and a beta of 1.11. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $26.00. The firm has a 50 day moving average of $21.66 and a 200-day moving average of $17.70.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.04. Analysts anticipate that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Several large investors have recently bought and sold shares of the stock. AJOVista LLC bought a new stake in shares of Enliven Therapeutics during the 4th quarter worth $28,000. SG Americas Securities LLC grew its holdings in Enliven Therapeutics by 17.8% during the 4th quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock valued at $187,000 after buying an additional 2,041 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Enliven Therapeutics in the fourth quarter worth approximately $66,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Enliven Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after purchasing an additional 1,029 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its position in Enliven Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock valued at $121,000 after acquiring an additional 2,208 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ELVN. Baird R W raised shares of Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Mizuho started coverage on shares of Enliven Therapeutics in a research report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price objective for the company. Finally, Robert W. Baird assumed coverage on shares of Enliven Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 target price for the company.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.